Startseite Kongressberichte & Archiv ASCO20 Virtual Scientific Meeting Oral Sessions Gastrointestinal Cancer I

Gastrointestinal Cancer—Colorectal and Anal

Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)

4000 A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.

Salvatore Siena, Maria Di Bartolomeo, Kanwal Pratap Singh Raghav, et al. 

The abstract concludes: 
Overall, T-DXd 6.4 mg/kg q3w demonstrated remarkable activity in pts with HER2-expressing mCRC refractory to standard therapies, with a safety profile consistent with previous results. ILD is an important risk and requires careful recognition and intervention. Clinical trial information: NCT03384940.
 
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:
view slide set

--------------------------------------------------------------------------------------------------------------------------------------------------------

4001 Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
 
Scott Kopetz, Axel Grothey, Eric Van Cutsem, et al.
 
The abstract concludes: 
The updated analysis of the BEACON CRC study confirmed that encorafenib + cetuximab with or without binimetinib improved OS and ORR in previously treated pts with BRAF V600E mCRC compared with standard chemotherapy. Clinical trial information: NCT02928224.

--------------------------------------------------------------------------------------------------------------------------------------------------------

4002 First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study.

Sara Lonardi, Marta Schirripa, Federica Buggin, et al.
 
The abstract concludes: 
Large prospective randomized studies in molecularly selected elderly mCRC are feasible with multicenter collaborative efforts. Primary EP was met in both treatment arms. 5FU/LV plus panitumumab for up to 12 cycles followed by panitumumab maintenance until PD might be a reasonable option in elderly mCRC patients with RAS/BRAF wt tumors deserving further investigations in phase III trials. Clinical trial information: NCT02904031.

--------------------------------------------------------------------------------------------------------------------------------------------------------

4003 Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.

Jeffrey A. Meyerhardt, Qian Shi, Charles S. Fuchs, et al. 
 
The abstract concludes: 
The addition of celecoxib to standard chemotherapy did not significantly improve DFS or OS. Clinical trial information: NCT01150045.

--------------------------------------------------------------------------------------------------------------------------------------------------------

4004 Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.
 
Alberto F. Sobrero, Thierry Andre, Jeffrey A Meyerhardt, et al.
 
The abstract concludes: 
5y OS rate reported in IDEA trials was higher than historical rates, regardless of duration of therapy. While overall survival in IDEA did not meet prior statistical assumptions for NI in overall population, the 0.4% difference in 5y OS should be placed in clinical context. OS and 5y DFS results continue to support the use of 3m adjuvant CAPOX for the vast majority of stage III colon cancer pts. This conclusion is strengthened by the substantial reduction of toxicities, inconveniencies and cost associated with shorter treatment duration. Clinical trial information: NCT01150045; 2009-010384-16; NCT00749450; ISRCTN59757862; 2007-003957-10; UMIN000008543; 2007-000354.

Read the comment in the ASCO DAILY NEWS:

Final IDEA Collaboration Results Support Just 3 Months of Adjuvant CAPOX for Most Patients With Stage III Colon Cancer

--------------------------------------------------------------------------------------------------------------------------------------------------------

4005 A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver metastasis from colorectal cancer: JCOG0603 study. 

Yukihide Kanemitsu, Yasuhiro Shimizu, Junki Mizusawa, et al.
 
The abstract concludes: 
DFS did not correlate with OS for LM. Postoperative chemotherapy with mFOLFOX6 improves DFS but worsens OS over surgery alone due to more deaths after recurrence in the CTX arm. Adjuvant mFOLFOX is not beneficial to patients after hepatectomy for LM. Clinical trial information: UMIN000000653.

--------------------------------------------------------------------------------------------------------------------------------------------------------

4006 Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial.
 
Geke Hospers, Renu R. Bahadoer, Esmee A. Dijkstra, et al. 
 
The abstract concludes: 
A lower rate of DrTF, as a result of a lower rate of distant metastases, in high-risk LARC patients can be achieved with preoperative short-course radiotherapy, followed by chemotherapy and TME than by conventional chemoradiotherapy. In addition, the high pCR rate, achieved with the experimental treatment regimen can contribute to organ preservation. This treatment can be considered as a new standard of care. Clinical trial information: NCT01558921.

--------------------------------------------------------------------------------------------------------------------------------------------------------

4007 Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.
 
Thierry Conroy, Najib Lamfichekh, Pierre-Luc Etienne, et al.
 
The abstract concludes: 
Neoadjuvant mFOLFIRINOX plus CRT is safe, and significantly increased ypCR rate, DFS and MFS. OS data are not mature. Clinical trial information: NCT01804790.

--------------------------------------------------------------------------------------------------------------------------------------------------------

4008 Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial. 
 
Julio Garcia-Aguilar, Sujata Patil, Jin K. Kim, et al. 
 
The abstract concludes: 
A WW strategy for patients with locally advanced rectal cancer that achieve a clinical complete response to TNT results in organ preservation for a high proportion of patients without compromising survival. Up-front CRT followed by consolidation chemotherapy resulted in a numerically higher WW rate compared to induction chemotherapy followed by CRT. Clinical trial information: NCT02008656.
--------------------------------------------------------------------------------------------------------------------------------------------------------
 
Choice of poster abstracts
4082 Efficacy of third-line anti-EGFR-based treatment (tx) versus (vs) Regorafenib/TAS-102 (R/T) according to primary tumor site in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts).
 
Raffaella Vivolo, Emilio Bria, Ina Valeria Zurlo, et al.
 
The abstract concludes:
Our study confirmed the results deriving from the retrospective analysis of the phase III study 20020408. Our results demonstrated a different benefit from third-line anti-EGFR tx according to primary tumor site, confirming the role of L-sided tumor in predicting benefit from third-line anti-EGFR vs R/T, while no difference was observed in R-sided tumors.
 
--------------------------------------------------------------------------------------------------------------------------------------------------------
 
4036 Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer patients: An AGEO prospective “real life” study.
 
Clélia Coutzac, Isabelle Trouilloud, Pascal Artru,et al.
 
The abstract concludes:
Efficacy and safety results in this real life prospective study are in line with those published phase III trials. Both treatments seem similar in term of efficacy favoring T for clinical use as shown by the higher number of patients receiving this drug.
 
--------------------------------------------------------------------------------------------------------------------------------------------------------
 
e-poster

e16053 Meta-analysis and systematic review of the cardiotoxicity of TAS-102

Carlos Alberto Lopez, Elham Azimi-Nekoo, Su Yun Chung, et al.

The abstract concludes:

Unlike other fluoropyrimidines, TAS-102 appears to be a cardiogentle drug, with no increased risk of cardiac events compared to placebo. Since fluoropyrimidines remain the backbone of treatment for gastrointestinal malignancies, TAS-102 can offer an alternative to patients who developed cardiotoxicities from other agents. Prospective studies with consideration of cardiac risk factors are required.

--------------------------------------------------------------------------------------------------------------------------------------------------------
 
MORE ABSTRACTS:
 
Poster Discussion Session
Gastrointestinal Cancer—Colorectal and Anal
 
Poster Session
Gastrointestinal Cancer—Colorectal and Anal
 

David H. Ilson: ASCO 2020 Report — Gastrointestinal Cancer Key trials in colorectal, esophageal, pancreatic, and hepatocellular cancer

 
 
ASCO Direct™ Focus – ASCO®20 Virtual Program  
Top presentations and expert interviews now available on demand!
Visit ascodirect2020.com and enter the following username „asco“ and password: „oncology"  
ASCO Direct Focus is an officially licensed online program for oncology professionals worldwide, providing complimentary access to an ASCO-curated selection of top presentations from the ASCO20 Virtual Scientific Program, plus expert commentaries.
Gastrointestinal (Abstracts #LBA4, 4000, 4002)
Access Content Now